How a medical device maker kept U.S. hospitals in the dark about deadly infections | Los Angeles Times
In 2012, a superbug outbreak sickened nearly two dozen patients who underwent duodenoscope procedures at a Dutch hospital. A consultant hired by the devicemaker, Olympus, concluded that the scopes could remain tainted after cleaning and should be recalled if additional issues were found. Olympus issued alerts in Europe, but did not bother to share the knowledge in the U.S., it's largest market, where the scopes were implicated in outbreaks sickening and killing dozens of patients last year.
Concurrent surgeries come under new scrutiny | Boston Globe
Following an earlier investigation on Massachusetts General Hospital surgeons leading concurrent or overlapping surgeries, a practice that is common but not commonly known by patients, the American College of Surgeons is launching a committee to draft guidelines for the practice and some hospitals are tightening restrictions on overlapping procedures.
U.S. probes Theranos complaints | Wall Street Journal
The Wall Street Journal reports that a former Theranos employee has filed a complaint with the CMS saying employees were forced to keep running tests using the Edison machine despite evidence of its inaccuracy, and another former employee has filed a complaint with the Food and Drug Administration claiming a study the testing company submitted as part of its application for approval to use the machine for herpes tests was marred by breaches in research protocol.
Martin Shkreli says drug-price hikes led to arrest | Wall Street Journal
Former Turing Pharmaceuticals executive Martin Shkreli says his arrest last week on securities fraud charges was motivated by the Daraprim price-hike and his brash persona, not the "Ponzi-like" scheme the feds allege he perpetrated while CEO of Retrophin.
Reuben Guttman: The lawyer pharma loves to hate | STAT
STAT interviews Reuben Guttman, a lawyer who specializes in pharmaceutical fraud and founding partner in the Washington practice of Guttman, Buchsner & Brooks. Guttman talks about the prevalence of fraudulent practices in the pharmaceutical industry.
